TATVA - Weekly AnalysisIn the Weekly Chart of TATVA ,
we can see that; it has made inside Decision making candle.
Enter on breaking its high with low as SL.
TATVA trade ideas
Tatva Chintan - Long Double BottomWeekly Double Bottom in Progress
Entry 1858
T1- 1988
T2- 2132
SL 1794
Tatva chitan Pharma double bottom Tatva chitan Pharma double bottom very attractive price, accumulate near bottom for short to medium term trade. Fundamentally good
TATVAIn the Weekly chart of TATVA ,
We can see that, it is holding strongly at 2000-2050 levels.
Lets see if it makes an uptrend or we will see new Lows below 2000 levels.
Tatva Chintan trading at its old resistanceTATVA CHINTAN trading near it's old resistance 2335. For further rally it needs to close above 2350 with high volume.
TARGET-3040
Tatva Chintan Pharma Chem LtdBuying zones buys small small quantities
if next q give good result seems on 3000 level asap.
No. Eq. Shares Cr 2.22
---------- Promoters+ - FIIs +- DIIs + Public +
sep 2021 79.17 3.53 7.36 9.94
Dec 2021 79.17 2.91 7.87 10.05
Mar 2022 79.17 3.05 8.13 9.65
Jun 2022 79.17 3.53 10.75 6.65
DII increases stake by 3.39%
increase your stake to slowly slowly..
Tatva Chintan for swing mark the levels and follow SL and target. Forming Ascending triangle pattern
Expecting Breakout ✌✌✌✌This scrip is expected to give breakout in the coming days. So traders keep on your radar to catch the momentum. Thanks to all 🙏🙏🙏
Buy Tatva fromed Cup and Handle patternBuy Tatva formed Cup and Handle pattern and also wait for green candle conformation then take entry tgrt 1:3 as per RR ratio
Tatva Chintan Pharma Cmp 2780 dated 12.1.2022Tatva Chintan Pharma Cmp 2780 dated 12.1.2022
1. Triangle Pattern on chart BO @ 2775
2. Rounding Pattern on RSI
Buy for a tgt of 3200+ SL 2665
It is just a view, pls trade at your own risk.
Short Term Pick ✌✌✌This scrip is expected to give short Term in the coming days. So traders keep on your radar to catch the momentum. Thanks to all 🙏🙏🙏
Buy Today, Sell Tomorrow: TATVA for more than 5%DON'T HAVE TIME TO MANAGE YOUR TRADES?
- Take BTST trades at 3:25 pm everyday
- Book profits within first 30 minutes of the market opening
- Try to exit taking 3-5% profit of each trade
- SL can be taken when 5/15 min candle close below 44EMA
Now why do I prefer BTST over swing trades? The primary reason is that I have observed that 90% of the stocks give most of the movement in just 1-2 days and the rest of the time they either consolidate or fall
TATVA CHINTAN : BREAKING OUT fundamentally very good stock, can be added for Long term
Fresh Breaking out of zone
TGT - 2950 & 3250(Hold it for long term)
Disclaimer
The analysis is only for illustration purposes only. Please consult your financial advisor, agent, broker before acting on any information. We may or may not have positions in the stock and our actions may be contrary to the one mentioned here. This analysis may or may not be updated. We would not be responsible for the profit/loss resulting from this analysis.
Buy for mid to long term in this COVID fear market without feaGood management
Product in agro-chemical and battery segment
Monopoly of few it's product
Convincing management
Growth outlook strong
Tatva ( technical following stock) This is simple price action of TATVA where green line means strong S & R
TATVA ready for some good movesTatva Chintan Pharma Chem Limited is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates, and other Speciality chemicals.
WHY IT MIGHT GIVE A GOOD MOVE NOW:
Tatva's IPO's QIB was oversubscribed by 185.23 times. Meaning, institutions that planned to buy 50,000 shares got only 269 shares in the allotment. After the IPO Listing, the price dropped by 20.62% obviously due to listing gains enjoyed by retailers. For 11 weeks the share price formed a base and gave good time for big hands to accumulate. On the 12th week the price broke out of the IPO Listing price with huge volumes (the day before & the day after also) Out of 5.29 lac shares traded that day, 3.23 lac were traded in the last 30 minutes. This confirms my hypothesis of the Entry of big hands during the breakout. The price then tested 2 times the IPO listing high and took good support on it.
Tatva's Q2 results also dropped on 22nd October (before 3 big volume days) and the Q2 numbers beat both QoQ & YoY numbers which might be the trigger.
Key Points of the Company
Leading Chemical Manufacturer
Tatva Chintan operates in the space of niche specialty chemicals and is a globally recognized specialty chemical player with several market-leading products in its portfolio. The co. is the largest and only commercial manufacturer of structure-directing agents for zeolites in India (second globally) and caters to a wide range of industries across the globe.
Product portfolio: The company has manufactured over 154 products which can be divided into the following four broad categories
Structure Directing Agents (40% of the revenue) The Company’s SDAs are quarternary salts which are chemicals used in the Zeolite application. Zeolites have varied applications it is promoted with transition metals such as copper and iron to be active for selective catalytic reduction.
Phase Transfer Catalysts (27% of the revenue) PTC’s are widely used in green chemistry applications and are used for a variety of industrial processes. Phase transfer catalysts are a type of catalyst that allows a reactant to be migrated from one phase to another.
Electrolyte salts for supercapacitor batteries (1% of the revenue) The Company’s electrolyte salts are used in the manufacture of supercapacitor batteries, which are used in automobile batteries and other batteries. The Company is the largest producer of electrolyte salts for supercapacitor batteries in India.
Pharmaceutical, agrochemicals, and other specialty chemicals (30% of the revenue) The products manufactured by the company under this category are used in the manufacture of various pharmaceutical and agrochemical products as intermediates, disinfectants, and catalysts, and solvents. In addition, the company also manufacture specialty chemicals under this category that are used in dyes and pigments, personal care ingredients, flavor, and fragrance sectors
The Company has 47 products under their SDA product portfolio, 48 products under the PTC product portfolio, 6 products under the electrolyte salts for supercapacitor batteries portfolio, and 53 products under their PASC portfolio.
Manufacturing facilities
The Company operates through two manufacturing facilities situated at Ankleshwar and Dahej in Gujarat, both of which are strategically located very close to the Hazira port. These manufacturing facilities have an annual installed reactor capacity of 280 KL and 17 Assembly Lines.
Exports-driven
The company derives a majority of its revenue through exports (71% of the revenue) with Germany, the U.S., and China together accounting for 54.20%. Its top 10 customers constitute 60% of revenue.
Clientele List
The customers of the Company include Merck, Bayer AG, Asian Paints Ltd., Ipox Chemicals KFT, Laurus Labs Ltd, Tosoh Asia Pte. Ltd., SRF Limited, Navin Fluorine International Limited, Oriental Aromatics Ltd., Atul Limited and many others.
R&D Infrastructure
The company has a dedicated R&D facility, recognized by the DISR at Vadodara, Gujarat. The company has developed 53 products in the last three years which contributed 6.5 Crs revenue for the company.
Successful listing
The company got listed on the secondary exchanges on July 29 2021 with a 114% premium from its issue price. The 500 Crs issue got subscribed 180 times and became the most over subscriber IPO of 2021. The issue constituted of 275 Crs Offer for sale by the promoters and a fresh issue of 225 Crs.
Growth Strategies:
Expanding the Manufacturing Capabilities:
The Company has consistently grown its manufacturing and production capabilities. The Company’s aggregate manufacturing capacity has increased at a CAGR of 20.59% from an aggregate reactor capacity of 82 KL and zero Assembly Lines in FY2010 to 280 KL Reactor Capacity and 17 Assembly Lines as of FY21. The company will expand its Dahej Manufacturing facility and upgrade its R&D Infra with a CAPEx to the tune of 170 Crs.
Expand the existing product portfolio
The Company plans to continue to increase offerings in their current business segments as well as diversify into new products by tapping into segments which in the view of the company’s management have attractive growth prospects.
Buy Tatva ChintanTatva Chintan can be looked at 2850 for MT to LT for the target of a double from here. Keep buying on declines.
